Category Archives: Diabetes News

Analysis of Hematological Parameters in Type 1 and Type 2 Diabetes Patients

Diabetes News


The following is a summary of “Changes in selected hematological parameters in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis,” published in the February 2024 issue of Hematology by Bambo et al.


Researchers conducted a retrospective study to uncover pooled mean differences in white and red blood cell parameters among diabetic patients, aiming to shed light on potential hematological imbalances in type 1 and type 2 diabetes mellitus.

Using appropriate entry terms, they extensively searched articles in various bibliographic databases, including PubMed, Cochrane Library, Scopus, Web of Science, PsycINFO, Embase, online archives, and university repositories. Relevant studies were identified based on eligibility criteria. Data, including author details, study characteristics, diabetes type, sample size, and hematological parameter means with SD, were extracted in Excel and analyzed in Stata 11. Pooled standardized mean difference (SMD) was determined with a random effects model, assessing heterogeneity using Higgins’ I2 statistics. Egger’s test and funnel plot analysis evaluated bias. A sensitivity analysis assessed the impact of small studies.

The results showed 39,222 articles following methodology screening, 22 articles with 14,041 participants (6,146 T2DM, 416 T1DM patients, and 7,479 HCs). Pooled SMD in TLC were 0.66, 109 for T2DM and -0.21 for T1DM. Absolute differential WBC counts in T2DM showed differences of 0.84 (neutrophils), -1.59 (eosinophils), 3.20 (basophils), 0.36 (lymphocytes), and 0.26 (monocytes). Relative differential counts in T2DM were neutrophils (1.31%), eosinophils (-0.99%), basophils (0.34%), lymphocytes (-0.19%), and monocytes (-0.64%). In T1DM, SMD of WBC  109 parameters were neutrophils (-0.10), lymphocytes (-0.69), monocytes (0.19), and basophils (-0.32). Pooled SMD in RBC parameters for T2DM were: RBC (-0.57, 106/μL), Hb (-0.73 g/dL), and HCT (-1.22%). In T1DM, RBC, Hb, and HCT were -1.23 (106/μL), -0.80 g/dL, and -0.29%, respectively.

They concluded that T2DM showed elevated white & specific cell types, while T1DM had decreased white & red blood cell parameters, highlighting diabetes’ impact on blood composition.

Source: frontiersin.org/articles/10.3389/fmed.2024.1294290/full



Source link

Convicted murderer and rapist Thabo Bester wants diabetes-friendly food, own clothes

Diabetes News
Thabo Bester appeared at the Free State High Court in Bloemfontein on Wednesday.


Thabo Bester appeared at the Free State High Court in Bloemfontein on Wednesday.

Thabo Bester appeared at the Free State High Court in Bloemfontein on Wednesday.

Convicted rapist and murderer Thabo Bester refused to eat before his court appearance and, as a result, could not take his diabetes medication, the Free State High Court in Bloemfontein heard on Wednesday.

But, along with several complaints, his lawyer told the court Bester refused to eat because the food was not appropriate for a diabetic person.

Bester and his lover, Dr Nandipha Magudumana, her father, Zolile Sekeleni; their gardener, Zanda Moyo; as well as Frans Makhotsa, Senohe Matsoara, Buti Masukela, Teboho Lipholo and Joel Maketha appeared for what was meant to be a pre-trial conference.

South Africans need to be in the know if we want to create a prosperous future. News24 has kept the country informed for 25 years, and we’re about to enter a new chapter of fearless journalism. Join our free subscription trial to unlock this story and a world of news aimed to inform, empower, and inspire.



Source link

‘I’m a diabetes doctor – these five exercises could keep blood sugar levels in check’

Diabetes News


Diabetes raises the spectre of dangerous complications posed by high levels of sugar in your blood.

Fortunately, lifestyle changes, including exercise, are some of the best weapons you can add to your arsenal of protection against dangerously high blood sugar levels.

Physical activity not only lowers your blood glucose levels, but it also boosts your body’s sensitivity to insulin, countering insulin resistance.

Insulin resistance occurs when your body’s cells don’t respond properly to insulin, leading to high blood sugar levels. However, exercise could make you more insulin sensitive, helping to manage high blood sugar levels more effectively.

Fortunately, a diabetes doctor has outlined the five best exercises for diabetics.

1.Walking

One of the most common exercises in the world, walking can be easily done anywhere you go.

An endocrine specialist, known on TikTok as The Voice of Diabetes, said: “What I recommend is about 30 minutes of brisk walking five times a week.”

2.Tai Chi

This Chinese martial arts practice is surprisingly good for lowering blood sugar levels, according to the diabetes specialist. She added: “It also helps your mental health. It helps people calm down. It involves a lot of slow different movements so Tai Chi is a great option.”

3.Yoga

This popular exercise has been proven to lower blood sugar levels, making a “great option” for diabetics.

4.Dancing

You might not associate dancing with exercise, but this fun physical movement could also benefit diabetics. The expert said: “Dancing is also good to lower blood sugar levels. And believe it or not, it actually helps your mental health.

“It can also reduce anxiety and depression. So I mean we could all benefit from some dancing.

5.Swimming

Swimming is another “wonderful option” for diabetics. The expert shared it can also stretch your muscles and joints.

The expert said: “It puts no strain on your joint muscles, so you don’t have to worry about knee replacement with swimming.”



Source link

Diabetes risk is noticeable in young Samoan children

Diabetes News
Measuring Blood sugar


Obesity is a serious problem worldwide, with over 4 million deaths yearly due to being overweight or obese. Even children are affected, with rates increasing dramatically since 1975. Nicola Hawley, from Yale, studies how obesity affects maternal and child health. She and her colleague, Courtney Choy, have been studying obesity in Samoa for almost ten years, focusing on child health in the Pacific.

A new study by Choy and Hawley revealed a significant rise in overweight or obese Samoan children, doubling from 16% to 36% between 2015 and 2020. In their latest research, published in Pediatric Obesity, they found alarming rates of diabetes and high blood pressure in children as young as 6 to 9 years old. About one in ten children showed signs of prediabetes. However, specific early growth patterns could predict these health issues, aiding clinicians in identifying children who may require intervention.

Choy, the study’s lead author, said, “Those worrisome levels in and of themselves motivate us to continue our work and better understand the state of obesity, diabetes, and hypertension in Samoa.”

Obesity is one part of malnutrition, with underweight and micronutrient deficiencies being the other, says WHO. Factors like imported, low-nutrient foods, and rising costs of local produce contribute to obesity in Samoa. Modernization has led to less active lifestyles and poorer diets.

Only a tiny percentage of women maintain a healthy weight in Samoa. Hawley and Choy’s study is the first to assess childhood heart and metabolic risks in a nation with high adult obesity rates. Their long-term study could help pinpoint the best times and methods for interventions against adult diseases.

The study began nine years ago with Samoa’s Ministry of Health, the Bureau of Statistics, and the Ministry of Women, Community, and Social Development. Choy, initially a YSPH student, recruited participants during her summer MPH internship with Samoa’s Ministry of Health. She continued the project with a Fulbright fellowship and later as a PhD at Brown University, funded by the NIH. An NIH K99 grant now supports Choy’s research. Her focus on Pacific health stems from her upbringing in Hawai’i.

Choy and Hawley, both at Yale, met early on. Hawley admires Choy’s determination and transition from student to independent investigator. They share a passion for improving health in Samoa.

Hawley and Choy’s study in Samoa examines how social and cultural factors affect children’s well-being. They aim to develop interventions by understanding what works best at different ages and how to prevent adult diseases.

After collecting data, Choy shares findings with village participants and engages children by involving them in the process. Next, they plan to gather participants’ input to address risk factors related to obesity, diabetes, and other health issues, ensuring children can achieve their aspirations.

Hawley and Choy’s study gives valuable insights into childhood well-being in Samoa. By understanding the social and cultural context, they aim to develop effective interventions to promote health and prevent diseases in children, thus enabling them to realize their dreams.

Journal reference:

  1. Avery A. Thompson, Rachel L. Duckham et al., Sex differences in the associations of physical activity and macronutrient intake with child body composition: A cross-sectional study of 3- to 7-year-olds in Samoa. Pediatric Obesity. DOI: 10.1111/ijpo.12603.



Source link

Milk May Lower T2D Risk in Patients With Lactose Intolerance

Diabetes News


Patients with lactose intolerance are usually advised to avoid milk. However, many still consume dairy products despite experiencing gastrointestinal symptoms. Surprisingly, this “unreasonable” strategy may have the benefit of reducing the risk for type 2 diabetes, as shown in a recent American study.

“At first glance, the statement of the study seems counterintuitive,” said Robert Wagner, MD, head of the Clinical Studies Center at the German Diabetes Center-Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany. “However, lactose intolerance has different manifestations.” Less severely affected individuals often consume milk and tolerate discomfort such as bloating or abdominal pain. “It is precisely these individuals that the study clearly shows have a lower incidence of diabetes associated with milk consumption,” said Wagner.

Milk’s Heterogeneous Effect

The effect of milk consumption on diabetes, among other factors, has been repeatedly studied in nutritional studies, with sometimes heterogeneous results in different countries. The reason for this is presumed to be that in Asia, most people — 60%-100% — are lactose intolerant, whereas in Europe, only as much as 40% of the population has lactose intolerance.

The authors, led by Kai Luo, PhD, research fellow in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine in Bronx, New York, did not mention lactose tolerance and intolerance in their paper in Nature Metabolism. Instead, they divided the study population into lactase-persistent and non-lactase-persistent participants.

“Not being lactase-persistent does not necessarily exclude the ability to consume a certain amount of lactose,” said Lonneke Janssen Duijghuijsen, PhD, a nutrition scientist at Wageningen University, Wageningen, the Netherlands. “Studies have shown that many individuals who lack lactase can still consume up to 12 g of lactose per day — equivalent to the amount in a large glass of milk — without experiencing intolerance symptoms.”

Gut Microbiome and Metabolites

Luo and his colleagues analyzed data from 12,653 participants in the Hispanic Community Health Study/Study of Latinos, an ongoing prospective cohort study involving adults with Hispanic backgrounds. It collects detailed information on nutrition and the occurrence of diseases.

The authors examined whether the study participants were lactase-persistent or non-lactase-persistent and how frequently they consumed milk. They also analyzed the gut microbiome and various metabolites in the blood over a median follow-up period of 6 years.

The data analysis showed that higher milk consumption in non-lactase-persistent participants — but not in lactase-persistent participants — is associated with about a 30% reduced risk for type 2 diabetes when socioeconomic, demographic, and behavioral factors are accounted for. Comparable results were obtained by Luo and his colleagues with data from the UK Biobank, which served as validation.

A higher milk consumption was associated not only with a lower diabetes risk in non-lactase-persistent individuals but also with a lower body mass index. “This could be one of the factors behind the diabetes protection,” said Wagner. “However, no formal mediation analyses were conducted in the study.”

Luo’s team primarily attributed the cause of the observed association between milk consumption and diabetes risk to the gut. Increased milk intake was also associated with changes in the gut microbiome. For example, there was an enrichment of Bifidobacterium, while Prevotella decreased. Changes were also observed in the circulating metabolites in the blood, such as an increase in indole-3-propionate and a decrease in branched-chain amino acids.

These metabolites, speculated the authors, could be more intensely produced by milk-associated bacteria and might be causally related to the association between milk consumption and reduced risk for type 2 diabetes in non-lactase-persistent individuals. “The authors have not been able to provide precise evidence of these mediators, but one possible mediator of these effects could be short-chain fatty acids, which can directly or indirectly influence appetite, insulin action, or liver fat beneficially,” said Wagner.

Bacteria in the Colon

For Janssen Duijghuijsen, the conclusion that milk consumption can influence the composition of the microbiome and thus the metabolic profile, especially in individuals without lactase persistence, is plausible.

“Individuals with lactase persistence efficiently digest lactose and absorb the resulting galactose and glucose molecules in the small intestine. In contrast, in non-lactase-persistent individuals, lactase is not expressed in the brush border of the small intestine. As a result, lactose remains undigested in the colon and can serve as an energy source for gut bacteria. This can influence the composition of the microbiome, which in turn can alter the concentration of circulating metabolites,” she said.

Janssen Duijghuijsen has investigated the effect of lactose intake on the microbiome. In a recently published study, she also showed that increasing lactose intake by non-lactase-persistent individuals leads to changes in the microbiome, including an increase in Bifidobacteria.

“In line with the current study, we also found a significant increase in fecal β-galactosidase activity. Given the close relationship between the composition of the gut microbiome and the metabolite profile, it is likely that changes in one can affect the other,” said Janssen Duijghuijsen.

Nutritional Recommendations

The nutrition scientist warned against concluding that milk consumption can protect against type 2 diabetes in non-lactase-persistent individuals, however. “The study suggests a statistical association between milk consumption, certain metabolites, and the frequency of type 2 diabetes. These associations do not provide definitive evidence of a causal relationship,” she said. Any dietary recommendations cannot be derived from the study; much more research is needed for that.

This story was translated from the Medscape German edition using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.



Source link

Two-Step Screening Uncovers Heart Failure Risk in Diabetes

Diabetes News


TOPLINE:

A two-step screening, using a risk score and biomarkers, can identify patients with diabetes at a higher risk for heart failure who will most likely benefit from preventive drugs.

METHODOLOGY:

  • Researchers compared screening methods and downstream risk for heart failure in 5 years, particularly those without atherosclerotic cardiovascular disease (ASCVD).
  • They pooled data from 4889 patients (age ≥ 40 years, about half women) with diabetes, no heart failure at baseline, and no signs of ASCVD. All patients had undergone screening to determine their heart failure risk level.
  • Researchers assessed the heart failure risk for patients without ASCVD with one-step screening strategies:
  • They next assessed a sequential two-step strategy, using the second test only for those deemed low risk by the first, with a combination of two tests (WATCH-DM/NT-proBNP, NT-proBNP/hs-cTn, or NT-proBNP/echocardiography), the second used for those deemed low-risk by the first test.
  • The primary outcome was incident heart failure during the 5-year follow-up. The researchers also assessed the cost-effectiveness of screening and subsequent treatment of high-risk patients with a sodium-glucose cotransporter 2 inhibitor.

TAKEAWAY:

  • Overall, 301 (6.2%) heart failure events occurred among participants without ASCVD.
  • Of the heart failure events, 53%-71% occurred among participants deemed high risk by a one-step screening strategy, but 75%-89% occurred among patients assessed as high risk in two steps.
  • The risk for incident heart failure was 3.0- to 3.6-fold higher in the high- vs low-risk group identified using a two-step screening approach.
  • Among the two-step strategies, the WATCH-DM score first, followed by selective NT-proBNP testing for patients deemed low risk by the first test, was the most efficient, with the fewest tests and lowest screening cost.

IN PRACTICE:

“Matching effective but expensive preventive therapies to the highest-risk individuals who are most likely to benefit would be an efficient and cost-effective strategy for heart failure prevention,” the authors wrote.

SOURCE:

The study led by Kershaw Patel of the Houston Methodist Academic Institute, Houston, Texas, was published online in Circulation.

LIMITATIONS:

The study findings may not be generalized, as the study included older adults with a high burden of comorbidities. This study may have missed some individuals with diabetes by defining it with fasting plasma glucose, which was consistently available across cohort studies, instead of with the limited A1c data. Moreover, the screening strategies used did not consider other important prognostic factors, such as diabetes duration and socioeconomic status.

DISCLOSURES:

Two authors declared receiving research support from the National Heart, Lung, and Blood Institute. Several authors disclosed financial relationships with multiple pharmaceutical device and medical publishing companies in the form of receiving personal fees; serving in various capacities such as consultants, members of advisory boards, steering committees, or executive committees; and other ties.



Source link

Kelly Clarkson’s weight loss came after she was diagnosed with pre-diabetes | Entertainment

Diabetes News


Kelly Clarkson decided to drop the pounds after being told she was pre-diabetic.

The 41-year-old singer was forced to explain her weight loss after it was rumoured she used weight-loss injections such as Ozempic, however, she has denied this to be the case, and revealed the health warning from her doctor was behind the shred.



Source link

AI Boosts Diabetic Eye Screening and Follow-Up in Youth

Diabetes News


TOPLINE:

Artificial intelligence (AI) boosts the screening rate for potentially blinding diabetes eye disorders in a diabetes clinic compared with referral to an eye care provider (ECP) in a racially and ethnically diverse youth population with diabetes.

METHODOLOGY:

  • Although early screening and treatment can prevent diabetic eye diseases (DEDs), many people with diabetes in the United States lack access to and knowledge about diabetic eye exams.
  • The ACCESS trial included 164 patients aged 8-21 years (58% female, 35% Black, and 6% Hispanic) with type 1 or 2 diabetes with no known DED and no diabetic eye exam in the last 6 months.
  • In a diabetes clinic, patients were randomly assigned to an AI diabetic eye exam (intervention arm) then and there or to standard of care, referred to an ECP with scripted educational material (control).
  • Participants in the intervention arm underwent the 5- to 10-minute autonomous AI diabetic eye exam without pharmacologic dilation. The results were generated immediately as either “DED present” or “DED absent.”
  • The primary outcome was the completion rate of documented diabetic eye exams within 6 months (“primary gap closure rate”), either by AI or going to the ECP. The secondary outcome was ECP follow-up by intervention participants with DED (intervention) and all control patients.

TAKEAWAY:

  • Within 6 months, all the participants (100%) in the intervention arm completed their diabetic eye exam, a primary care gap closure rate of 100% (95% CI, 96%-100%).
  • The rate of primary care gap closure was significantly higher in the intervention vs control arm (100% vs 22%; P < .001).
  • In the intervention arm, 64% of patients with DED followed up with an eye care provider within 6 months compared with a mere 22% participants in the control arm (P < .001).
  • Participants reported high levels of satisfaction with autonomous AI, with 92.5% expressing satisfaction with the exam’s duration and 96% expressing satisfaction with the whole experience.

IN PRACTICE:

“Autonomous AI increases diabetic eye exam completion rates and closes this care gap in a racially and ethnically diverse population of youth with diabetes, compared to standard of care,” the authors wrote.

SOURCE:

This study, which was led by Risa M. Wolf, MD, Department of Pediatrics, Division of Endocrinology, Johns Hopkins School of Medicine, Baltimore, Maryland, was published online on January 11, 2024, in Nature Communications.

LIMITATIONS:

This study used autonomous AI in the youth although it’s not approved by the US Food and Drug Administration for use in individuals aged 21 years and younger. Some of the participants in this study were already familiar with autonomous AI diabetic eye exams, which might have contributed to their willingness to participate in the current study. The autonomous AI used in the study was shown to have a lack of racial and ethnic bias, but any AI bias caused by differences in retinal pigment has potential to increase rather than decrease health disparities.

DISCLOSURES:

The clinical trial was supported by the National Eye Institute of the National Institutes of Health and the Diabetes Research Connection. Wolf, the lead author, declared receiving research support from Boehringer Ingelheim and Novo Nordisk outside the submitted work. Co-author Michael D. Abramoff declared serving in various roles such as investor, director, and consultant for Digital Diagnostics Inc., as well as other ties with many sources.



Source link

Global Diabetes Therapeutics and Diagnostics Set to Hit $132.0 Billion in 2028- Insights from BCC Research

Diabetes News


Latest Study Forecasts Global Diabetes Therapeutics and Diagnostics Market to Surge to $132 Billion by 2028, Growing at a 5.2% CAGR

BOSTON, Jan. 16, 2024 /PRNewswire/ — The global market for diabetes therapeutics and diagnostics is experiencing remarkable growth, poised to reach $132.0 billion by 2028. Fueled by increasing diabetes prevalence and technological advancements, this market is at the forefront of healthcare innovation. In this overview, we explore the key factors propelling its expansion, highlighting the intersection of research, pharmaceutical development, and diagnostic technologies shaping the landscape of diabetes management worldwide. Join us as we navigate the dynamic trends and impactful solutions driving the global markets for diabetes therapeutics and diagnostics.

“According to the latest research study, the demand for Global Markets for Diabetes Therapeutics and Diagnostics to increase from $102.2 billion in 2023 to reach $132.0 billion by 2028, at a compound annual growth rate (CAGR) of 5.2% from 2023 through 2028.”

This comprehensive report delves into the far-reaching implications of current trends within the diabetes therapeutics and diagnostics market, offering insights into the market’s size, growth trajectory, and its impact on both global and key national markets. A thorough exploration of pharmaceutical and medical industry players is provided, including profiles of industry leaders and updates on mergers and acquisitions. The report further includes a detailed discussion on competitive intelligence, innovative technologies, market dynamics, and regional opportunities. Notably, it furnishes five-year global sales forecasts for leading drug and device categories, complemented by country-level breakdowns. The analysis extends to major players’ recent developments and product portfolios, with a keen focus on patent analysis to highlight technological trends across the U.S., Europe, and Japan. The market analysis culminates in estimates of the compound annual growth rate (CAGR) for the diabetes therapeutics and diagnostics market. Geographically, the report segments the global market into North America, Europe, Asia-Pacific, and the Rest of the World, utilizing 2022 as the base year for market estimates, projecting through year-end 2028.

The Diabetes Delivery Devices segment has experienced exceptional growth, particularly fueled by technological advancements like implantable insulin delivery pumps and external insulin pumps. Notably, the integration of wireless technology and miniaturization in medical device components is anticipated to spur innovation in diabetes care devices, thereby propelling market growth throughout the forecast period. The adoption of cutting-edge technologies such as 3D printing, artificial intelligence, and big data analytics in device manufacturing is contributing to reduced operating costs and enhanced product quality. Within the Asia Pacific region, India stands out with the highest growth rate, propelled by supportive government policies, increased awareness about diabetes, and the presence of dedicated associations and societies for diabetes control and monitoring. This growth trajectory positions India as a key player in the region, potentially surpassing the pace observed in the U.S. and other nations in the Asia Pacific region.

Discover More: Dive into the Details of the Global Markets for Diabetes Therapeutics and Diagnostics Market’s Growth Trajectory and Future Prospects. Click Here to Learn More

Driving forces behind the global markets for diabetes therapeutics and diagnostics market’s insights growth comprises:

  1. Increasing incidence & prevalence of diabetes- The increasing incidence and prevalence of diabetes globally have become a significant public health concern. The World Health Organization (WHO) estimates that the number of people with diabetes has risen sharply over the past few decades, reaching an alarming prevalence. Factors such as sedentary lifestyles, unhealthy dietary habits, and rising obesity rates contribute to the surge in diabetes cases. The condition not only poses immediate health risks but also leads to long-term complications such as cardiovascular diseases, kidney failure, and blindness. The economic burden of diabetes on healthcare systems is substantial, emphasizing the urgent need for effective preventive measures, education, and accessible healthcare resources to address and manage this growing health crisis.
  2. Changing lifestyle habits- Changing lifestyle habits have emerged as a key factor influencing health outcomes worldwide. In recent decades, a shift towards sedentary routines, poor dietary choices, and increased stress levels has significantly impacted public health. Sedentary lifestyles, characterized by reduced physical activity, contribute to the rising incidence of health issues such as obesity, cardiovascular diseases, and diabetes. Unhealthy dietary habits, often marked by high consumption of processed foods and sugary beverages, further exacerbate these health concerns. The modern pace of life, with heightened work-related stress and irregular sleep patterns, also plays a role in compromising overall well-being. Recognizing the impact of lifestyle choices on health, there is a growing emphasis on promoting healthier habits through education, awareness campaigns, and policy interventions to foster positive changes in daily routines and improve long-term health outcomes.
  3. Growing geriatric population– The growing geriatric population represents a significant demographic shift with profound implications for healthcare systems worldwide. As advancements in healthcare contribute to increased life expectancy, the proportion of elderly individuals is on the rise. This aging demographic trend is associated with a higher prevalence of chronic conditions and age-related health issues, placing additional demands on healthcare infrastructure and resources. Conditions such as cardiovascular diseases, osteoporosis, and neurodegenerative disorders become more prevalent in older age groups, necessitating specialized and comprehensive healthcare services. Addressing the unique healthcare needs of the elderly, including preventive measures, specialized medical care, and social support systems, becomes crucial in ensuring a healthy and dignified aging process for this expanding segment of the population. The phenomenon of a growing geriatric population underscores the importance of proactive healthcare planning and strategies to meet the evolving needs of an aging society.
  4. Increase in prevalence of chronic diseases- The increase in the prevalence of chronic diseases represents a global health challenge, with far-reaching implications for individuals, healthcare systems, and economies. Chronic diseases, such as heart disease, diabetes, and respiratory conditions, have become more prevalent due to factors like aging populations, changing lifestyles, and environmental influences. These conditions often require long-term management and care, placing a substantial burden on healthcare resources. The rise in chronic diseases not only impacts the quality of life for affected individuals but also contributes significantly to healthcare costs. Prevention and early intervention strategies, along with lifestyle modifications, are crucial in mitigating the growing burden of chronic diseases. Addressing this trend requires a comprehensive and coordinated approach, involving public health initiatives, medical research, and innovative healthcare delivery models to promote healthier living and enhance the management of chronic conditions on a global scale.

Request a Copy of the Global Markets for Diabetes Therapeutics and Diagnostics

Report Synopsis        

Report Metrics

Details

Base year considered

2022

Forecast Period considered

2023-2028

Base year market size

$97.3 billion

Market Size Forecast

$132.0 billion

Growth Rate

CAGR of 5.2% for the forecast period of 2023-2028

Segment Covered

Product Group, End-User, and Region

Regions covered

North America, Europe, Asia-Pacific, and Rest of the World (RoW).

Countries covered

U.S., Canada, Mexico, France, Germany, U.K., Italy, Spain, China, India, and Japan

Key Market Drivers

•  Increasing incidence & prevalence of diabetes

•  Changing lifestyle habits

•  Growing geriatric population

•  Increase in prevalence of chronic diseases

The Rising Demand for Global Markets for Diabetes Therapeutics and Diagnostics:

The escalating demand for global markets in diabetes therapeutics and diagnostics is indicative of the increasing prevalence of diabetes and the imperative for advanced healthcare solutions. With the market projected to reach $132.0 billion by 2028, the surge is fueled by a combination of technological innovations, heightened awareness, and the continuous pursuit of more effective treatment and diagnostic options. The escalating demand is not only a testament to the growing burden of diabetes but also underscores the vital role of pharmaceutical advancements and diagnostic technologies in addressing this global health challenge. As countries grapple with rising diabetes rates, the demand for cutting-edge therapeutics and diagnostics is a driving force propelling this market’s growth, emphasizing the urgent need for comprehensive solutions to better manage and combat the diabetes epidemic on a worldwide scale.

Trends and Innovations:

The landscape of global markets for diabetes therapeutics and diagnostics is shaped by dynamic trends and ongoing innovations. Notably, the Diabetes Delivery Devices segment has witnessed remarkable growth, propelled by technological advancements like implantable insulin delivery pumps and external insulin pumps. The integration of wireless technology and miniaturization in medical device components is fostering innovation in diabetes care, while 3D printing, artificial intelligence, and big data analytics are driving manufacturing efficiency. Amidst these trends, India stands out in the Asia Pacific region with the highest growth rate, supported by government policies, heightened diabetes awareness, and dedicated associations. These trends underscore a transformative era in diabetes management, where technological advancements and strategic initiatives converge to address the evolving needs of patients and healthcare systems globally.

Challenges and Opportunities:

The global markets for diabetes therapeutics and diagnostics present a landscape of both challenges and opportunities. The increasing prevalence of diabetes poses a substantial challenge to healthcare systems globally, necessitating innovative and scalable solutions. Rising healthcare costs, coupled with the complexities of managing chronic conditions, contribute to the challenges faced by the industry. However, within these challenges lie significant opportunities for growth and improvement. Technological advancements offer the potential for more efficient and effective diabetes management, from innovative therapies to advanced diagnostic tools. Additionally, the growing awareness of diabetes and proactive government policies present opportunities for market expansion, especially in regions like India, where a higher growth rate is anticipated. Successfully navigating these challenges and leveraging the opportunities can lead to transformative breakthroughs in diabetes care, benefiting both patients and the broader healthcare ecosystem.

This report on the Global Markets for Diabetes Therapeutics and Diagnostics provides comprehensive insights and analysis, addressing the following key questions:

  1. What are the anticipated dimensions and expansion pace of the diabetes therapeutics and diagnostics market?

    The market is expected to witness an increase from $97.2 billion in 2022 to $132.0 billion by 2028, with a compound annual growth rate (CAGR) of 5.2% throughout the forecast period.

  2. What factors contribute to the growth of the diabetes therapeutics and diagnostics market? 

    The market is experiencing growth driven by the increasing incidence and prevalence of diabetes, advancements in technology related to diabetes treatment and diagnostics, and strategic initiatives undertaken by major players in developed nations.

  3. What divisions are included in the diabetes therapeutics and diagnostics market?

    The market is categorized based on product group, end-user, and region. 

  4. Which segment is projected to lead the market by the conclusion of 2028 in terms of product groups? 

    The Diabetes Therapeutics segment is anticipated to dominate the market by the end of 2028. 

  5. In the diabetes therapeutics and diagnostics market, which region commands the greatest market share?

    North America boasts the highest market share in this sector.

  6. Which companies or players are prominent in the diabetes therapeutics and diagnostics market? 

    Key players in the market encompass Novo Nordisk A/S, Lilly, Boehringer Ingelheim International GmbH, AstraZeneca, Abbott, Merck & Co., Inc., Sanofi, Dexcom, Inc., Medtronic, and others.

Some of the Key Market Players Are:

  • 77 ELEKTRONIKA KFT.
  • ABBOTT
  • ALTUCELL
  • ASCENSIA DIABETES CARE HOLDINGS AG.
  • ASTRAZENECA
  • B. BRAUN SE
  • BIOCON
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • DANAHER
  • DEXCOM INC.
  • EMBECTA CORP.
  • INSULET CORPORATION.
  • JOHNSON & JOHNSON SERVICES INC.
  • LIFESCAN IP HOLDINGS LLC
  • LILLY
  • MEDTRONIC
  • MENARINI GROUP (A. MENARINI DIAGNOSTICS S.R.L)
  • MERCK & CO. INC.
  • MERCK KGAA
  • NEXTCELL PHARMA AB
  • NIPRO
  • NOVA BIOMEDICAL
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • ROCHE (F. HOFFMANN-LA ROCHE LTD)
  • SANOFI
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED.
  • TANDEM DIABETES CARE INC.
  • TERUMO CORPORATION
  • YPSOMED AG

Browse More Related Reports: 

Global Markets for Stem Cells: The global market for stem cells is characterized by dynamic advancements in regenerative medicine, offering promising avenues for therapeutic applications. Stem cells, known for their unique ability to differentiate into various cell types, hold immense potential for treating a range of diseases and injuries. This burgeoning market involves diverse sectors such as stem cell-based therapies, research tools, and regenerative medicine applications. Major players in the industry include notable biotechnology and pharmaceutical companies, as well as academic and research institutions. As the field continues to evolve, the global markets for stem cells are poised for significant growth, fueled by ongoing research breakthroughs, clinical trials, and increasing awareness of the transformative potential of stem cell-based therapies. The intersection of scientific innovation, regulatory advancements, and expanding therapeutic possibilities underscores the key role of stem cells in shaping the future of medicine and healthcare.

DNA Vaccines: Technologies and Global Markets: The realm of DNA vaccines represents a cutting-edge frontier in the field of immunization, combining genetic engineering and vaccination technologies. This market is characterized by the development and utilization of vaccines that leverage the genetic material of pathogens to stimulate an immune response. As a promising alternative to traditional vaccines, DNA vaccines offer advantages such as rapid development, scalability, and potential broader applicability across various diseases. Key players in this market include biotechnology companies, pharmaceutical firms, and research institutions driving innovation in vaccine development. The global market for DNA vaccines is witnessing significant growth, propelled by advancements in biotechnology, increased understanding of genetic immunization, and the ongoing pursuit of effective and versatile vaccine solutions against infectious diseases and other health challenges. As research and development efforts continue, the market for DNA vaccines is poised to play a pivotal role in shaping the future of preventive medicine on a global scale.

Directly Purchase a copy of the report with BCC Research.

For further information or to make a purchase, please get in touch with [email protected].  

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts’ goal is to help you make informed business decisions, free of noise and hype.

Contact Us

Corporate HQ: BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, USA

Email: [email protected] 
Phone: +1 781-489-7301

For media inquiries, email [email protected] or visit our media page for access to our market research library.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

SOURCE BCC Research LLC



Source link

1 2 3 11